相关实验视频

Updated: Jan 16, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

免疫治疗在高血压的高级非小细胞肺癌中的应用:多中心回顾性分析

Jingyi Yuan¹, Kaixin Lei¹, Quanling Kong¹

¹West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in oncology

|September 29, 2025

概括

高血压与接受免疫治疗的高级非小细胞肺癌 (NSCLC) 患者的生存率较差有关. 非高血压NSCLC患者的死亡风险较低,突出显示高血压是潜在的预后因素.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
心血管并发症心血管并发症

背景情况:

免疫检查点抑制剂 (ICI) 是高级非小细胞肺癌 (NSCLC) 的标准.
在接受免疫治疗的NSCLC患者中高血压 (HTN) 的预后作用尚不清楚.
HTN是已知的癌症风险因素,但它对癌症预后的影响需要进一步调查.

研究的目的:

研究在接受免疫治疗的晚期NSCLC患者中高血压和预后之间的关联.
为了确定ICI治疗的晚期NSCLC患者的潜在预后因素.

主要方法:

对接受免疫治疗的晚期NSCLC患者 (IIIb-IV阶段) 的回顾性分析.
使用考克斯比例危险模型和卡普兰-梅尔方法分析的无进展生存率 (PFS) 和整体生存率 (OS).
对高血压NSCLC患者的亚组分析.

主要成果:

与高血压组相比,非高血压组的整体存活时间 (OS) 显着更长 (P=0.049).
在多变量分析中,2的ECOG性能状态与OS有显著的相关性 (HR=0.73,P=0.037).
PD-1/PD-L1治疗显示与PFS有显著的关联 (HR=1.27,P=0.050).

结论:

高血压与接受免疫治疗的晚期NSCLC患者的死亡风险较低有关.
在亚组分析期间,高血压NSCLC患者的生存预后与基线指标没有显著相关.
高血压可能是接受免疫治疗的高级NSCLC患者的重要预后因素,这需要通过未来的试验进一步验证.

关键词:

这是一种PD-1/PD-L1抑制剂.这种高血压,高血压.免疫检查点抑制剂免疫检查点抑制剂非小细胞肺癌的肺癌.预后预后预后

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Hypertension V: Nursing Management

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.